European Commission Approves Expanded Use of Opdivo® (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

- Mar 05, 2019-

  This approval expands Opdivo’s existing lung cancer indication in previously treated metastatic squamous NSCLC to include the non-squamous patient population, which together represents 85% of lung cancer cases

   Opdivo is the only PD-1 inhibitor approved for a broad range of patients with previously treated metastatic NSCLC, regardless of PD-L1 expression

   Opdivo represents the first and only approved PD-1 inhibitor to demonstrate superior overall survival compared to docetaxel, in previously treated metastatic NSCLC